Leopoldo Soares Piegas
A5066263534- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Venous Thromboembolism Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac and Coronary Surgery Techniques
- Cardiac Arrhythmias and Treatments
- Public Health in Brazil
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Infective Endocarditis Diagnosis and Management
- Mechanical Circulatory Support Devices
- Blood Pressure and Hypertension Studies
- Healthcare during COVID-19 Pandemic
- Healthcare Regulation
- Cardiac Structural Anomalies and Repair
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Disease and Adiposity
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Acute Ischemic Stroke Management
Hospital do Coração
2008-2024
Sociedade Brasileira de Cardiologia
2005-2021
Universidade de São Paulo
2013-2020
Population Health Research Institute
2008-2020
Hamilton Health Sciences
2000-2020
McMaster University
2008-2020
Hospital São Paulo
2016-2018
Instituto Dante Pazzanese de Cardiologia
2007-2016
University College Hospital at Westmoreland Street
2016
University College London
2016
We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than for secondary cardiovascular prevention.In this double-blind trial, we randomly assigned 27,395 participants stable atherosclerotic vascular disease to receive (2.5 mg twice daily) plus (100 once daily), (5 daily). The primary outcome was a composite of death, stroke, myocardial infarction. study stopped superiority the rivaroxaban-plus-aspirin group after mean follow-up 23 months.The occurred...
Previous trials have shown that the use of statins to lower cholesterol reduces risk cardiovascular events among persons without disease. Those involved with elevated lipid levels or inflammatory markers and mainly white persons. It is unclear whether benefits can be extended an intermediate-risk, ethnically diverse population
Although unstable coronary artery disease is the most common reason for admission to a care unit, long-term prognosis of patients with this diagnosis unknown. This particularly true diabetes mellitus, who are known have high morbidity and mortality after an acute myocardial infarction.Prospectively collected data from 6 different countries in Organization Assess Strategies Ischemic Syndromes (OASIS) registry were analyzed determine 2-year diabetic nondiabetic hospitalized angina or...
ContextGlucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, large, adequately powered randomized trial required determine effect on STEMI.ObjectiveTo high-dose STEMI.Design, Setting, and ParticipantsRandomized controlled conducted 470 centers worldwide among 20 201 STEMI who presented...
The relative benefits and risks of performing coronary-artery bypass grafting (CABG) with a beating-heart technique (off-pump CABG), as compared cardiopulmonary (on-pump are not clearly established.
Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and those with a systolic blood pressure 160 mm Hg or higher, but its role in at intermediate lower is unclear.In one comparison from 2-by-2 factorial trial, we randomly assigned 12,705 participants who did not have disease to receive either candesartan dose 16 mg per day plus hydrochlorothiazide 12.5 placebo. The first coprimary outcome was composite death causes, nonfatal myocardial infarction,...
Several trials have been performed in the past using glucose, insulin, and potassium infusion (GIK) for treatment of acute myocardial infarction (AMI). Because continuing uncertainty about potential role this therapeutic intervention, we conducted a randomized trial to evaluate impact GIK solution during first hours AMI.Four hundred seven patients with suspected AMI admitted within 24 symptoms onset were enrolled. In ratio 2:1, 268 allocated receive (high- or low-dose) 139 control. Phlebitis...
Lamy, André*; Devereaux, P.J.*; Prabhakaran, Dorairaj†; Taggart, David P.‡; Hu, Shengshou§; Paolasso, Ernesto∥; Straka, Zbynek¶; Piegas, Leopoldo S.#; Akar, Ahmet Ruchan**; Jain, Anil R.††; Noiseux, Nicolas‡‡; Padmanabhan, Chandrasekar§§; Bahamondes, Juan-Carlos∥∥; Novick, Richard J.¶¶; Vaijyanath, Prashant##; Reddy, Sukesh***; Tao, Liang†††; Olavegogeascoechea, Pablo A.‡‡‡; Airan, Balram§§§; Sulling, Toomas-Andres∥∥∥; Whitlock, P.*; Ou, Yongning*; Ng, Jennifer*; Chrolavicius, Susan*; Yusuf,...
Previously, we reported that there was no significant difference at 30 days in the rate of a primary composite outcome death, myocardial infarction, stroke, or new renal failure requiring dialysis between patients who underwent coronary-artery bypass grafting (CABG) performed with beating-heart technique (off-pump) and those CABG cardiopulmonary (on-pump). We now report results on quality life cognitive function clinical outcomes 1 year.
We previously reported that there was no significant difference at 30 days or 1 year in the rate of composite outcome death, stroke, myocardial infarction, renal failure between patients who underwent coronary-artery bypass grafting (CABG) performed with a beating-heart technique (off-pump) and those CABG cardiopulmonary (on-pump). now report results 5 years (the end trial).A total 4752 (from 19 countries) had coronary artery disease were randomly assigned to undergo off-pump on-pump CABG....
Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce events substantially.
Background— During follow-up of between 1 and 3 years in the Randomized Evaluation Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses dabigatran etexilate were shown to be effective safe for prevention stroke or systemic embolism patients with atrial fibrillation. There is a need longer-term on further data comparing doses. Methods Results— Patients randomly assigned RE-LY eligible Multicenter Extension Dabigatran Treatment Atrial Fibrillation (RELY-ABLE) trial if they had not...
Background: Few studies have prospectively and systematically explored the factors that acutely precipitate exacerbation of congestive heart failure (CHF) in patients with left ventricular dysfunction.Knowledge such is important designing measures to prevent deterioration clinical status.The objective this study was describe precipitants associated CHF status enrolled Randomized Evaluation Strategies for Left Ventricular Dysfunction Pilot Study.Methods: We conducted a 2-stage, multicenter,...
Background Other than aspirin, there are few oral antithrombotic treatments with proven efficacy in patients acute coronary syndrome. In this report, we present the rationale, design and baseline characteristics of Clopidogrel Unstable angina to prevent Recurrent ischaemic Events (CURE) trial, which includes a meta-analysis effects thienopyridines vascular disease.
Patients with established coronary artery disease or peripheral often have diabetes mellitus. These patients are at high risk of future vascular events.In a prespecified analysis the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared effects rivaroxaban (2.5 mg twice daily) plus aspirin (100 versus placebo in mellitus without preventing major events. The primary efficacy end point was composite cardiovascular death, myocardial infarction, stroke....
1. Epidemiologia da Parada Cardiorrespiratoria e Apresentacao Diretriz […] Atualizacao de Ressuscitacao Cardiopulmonar Cuidados Cardiovasculares Emergencia Sociedade Brasileira Cardiologia – 2019
Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instavel e Infarto Agudo do Miocardio sem Supradesnivel Segmento ST – 2021